Previous Close | 84.74 |
Open | 84.25 |
Bid | 84.15 x 700 |
Ask | 84.22 x 700 |
Day's Range | 84.01 - 84.93 |
52 Week Range | 62.07 - 87.87 |
Volume | |
Avg. Volume | 6,550,909 |
Market Cap | 104.791B |
Beta (5Y Monthly) | 0.20 |
PE Ratio (TTM) | 102.65 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 3.08 (3.66%) |
Ex-Dividend Date | Sept 13, 2024 |
1y Target Est | N/A |
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.